17 May 2018 San Mateo, CA – May 16th, 2018: Adherium (ASX: ADR), an award-winning digital health company that improves medication adherence, patient outcomes and engagement, today announced the launch of the Hailie™ global brand to connect people with asthma and COPD to better care. The launch is a rebrand of the existing Smartinhaler™ brand, and […]
15 May 2018 San Mateo, CA – May 1, 2018: Adherium, an award-winning digital health company that improves medication adherence and patient outcomes, today announced the Company will be participating in the upcoming Chardan Digital Health Conference in San Francisco, CA on Tuesday, May 22, 2018. Arik Anderson, CEO, is scheduled to provide a business overview […]
01 May 2018 San Mateo, CA – May 1, 2018: In conjunction with World Asthma Day, Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, announced today it has agreed to launch a program with Vitalus Health, targeting patients with chronic obstructive pulmonary disease (COPD) using the Adherium Smartinhaler technology. Vitalus […]
San Mateo, CA – March 27, 2018: Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, today announced the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for over-the-counter (OTC) sales of its SmartinhalerTM sensor for AstraZeneca’s Symbicort® aerosol asthma inhaler. The Smartinhaler sensor is a device installed onto a […]
12 Mar 2018 SAN MATEO, Calif., March 12, 2018 (GLOBE NEWSWIRE) — Adherium (ASX:ADR), a digital health company that improves medication adherence and patient outcomes, today announced that members of its Board of Directors recently purchased approximately 1.4 million shares on the open market. The timing of these purchases complied with the Company’s “blackout period” […]
26 Jan 2018 San Mateo, CA – January 26, 2018: Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, today announced Tim Houchin as Vice President of Sales. “Tim brings to our sales effort a sophisticated understanding of the intersection of wearables and healthcare as well as how to reach consumers […]
21 Dec 2017 San Mateo, CA – December 20, 2017: Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, today highlighted milestones achieved in advance of 2018. “As we conclude December and the calendar year, we are accelerating realization of our vision of stronger partnerships between patients and physicians, facilitated by […]
Adherium today announced it has released SmartTurbo Model 4, the next generation of the company’s adherence monitoring technology, for AstraZeneca’s Turbuhaler medication. SmartTurbo Model 4 includes usability improvements to make the installation and removal of the Turbuhaler easier for older patients with COPD. The device also features a series of new larger buttons that help patients easily access new optional […]
04 Sep 2017 – link here We’re thrilled to announce that Adherium has received U.S. Food and Drug Administration (FDA) 510(K) clearance for its new SmartTouch for Symbicort® inhaler monitoring device for AstraZeneca’s Symbicort aerosol inhaler. The SmartTouch for Symbicort® is a device installed onto a patient’s inhaler to monitor and encourage medication adherence as part of a self-management […]
9 June 2017:link here Adherium Limited (ASX : ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced the appointment of Arik Anderson as Group Chief Executive Officer (CEO). Founder and past Group CEO, Garth Sutherland, welcomed the appointment of Arik as a key step in the […]